Related Experiment Video
Updated: Dec 30, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses
Bin Luo1, Lanshan Huang2, Yongyao Gu2
1Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Abstract:
Exportin-1 (XPO1) is an essential nuclear export receptor that is involved in the pathogenesis of multiple tumors. However, the role of XPO1 in diffuse large B-cell lymphoma (DLBCL) requires clarification. This study aims to detect XPO1 expression in DLBCL and to explore its relationships with clinicopathologic parameters and prognoses.
Methods:
A total of 131 cases of DLBCL and 30 cases of reactive lymphoid hyperplasia were selected for immunohistochemistry to examine XPO1 expression and analyze the relationships of XPO1 expression with clinicopathologic parameters and prognosis. DLBCL datasets downloaded from The Cancer Genome Atlas (TCGA) were used to analyze the mutations, expressions, and clinical values of XPO1 in DLBCL.
Results:
XPO1 expression was markedly upregulated in DLBCL compared to the reactive lymphoid hyperplasia group (χ2 = 10.734, P = 0.001). High XPO1 expression was associated with an advanced clinical stage (χ2 = 4.036, P = 0.045) and a risky International Prognostic Index (IPI) score (χ2 = 5.301, P = 0.025). Moreover, high XPO1 expression was associated with a lower overall survival rate compared with low expression (P = 0.043). XPO1 was an independent prognostic factor for DLBCL (risk ratio, RR = 3.772, P = 0.006). Furthermore, XPO1 overexpression in DLBCL was correlated with a high IPI score (P = 0.024) in TCGA datasets.
Conclusion:
High XPO1 expression in DLBCL was related to an advanced clinical stage, poor IPI score, and poor prognosis. Thus, XPO1 may be useful for condition identification and prognostic assessment.
